Amgen Inc. $AMGN Stock Position Cut by King Luther Capital Management Corp

King Luther Capital Management Corp decreased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 490,602 shares of the medical research company’s stock after selling 2,563 shares during the period. Amgen makes up 0.9% of King Luther Capital Management Corp’s investment portfolio, making the stock its 29th biggest holding. King Luther Capital Management Corp’s holdings in Amgen were worth $206,794,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. State Street Corp raised its position in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. Bank of America Corp DE acquired a new position in Amgen during the 2nd quarter worth approximately $1,831,903,000. Wellington Management Group LLP boosted its position in Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after acquiring an additional 2,514,254 shares during the last quarter. BlackRock Inc. grew its stake in shares of Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Amgen by 702.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after acquiring an additional 1,344,010 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of AMGN opened at $468.11 on Thursday. The company has a market cap of $253.21 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 3.25 and a beta of 0.43. Amgen Inc. has a 1-year low of $312.39 and a 1-year high of $483.99. The company’s fifty day simple moving average is $424.39 and its 200 day simple moving average is $380.01. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.64 earnings per share. On average, research analysts forecast that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is presently 58.47%.

More Amgen News

These are some of the AMGN news items that stood out recently:

  • Positive Sentiment: Dazodalibep met the primary endpoint in the 648-patient OASIZ-301 trial, with both dosing regimens producing statistically significant reductions in systemic disease activity versus placebo over 48 weeks. Amgen also reported clinically meaningful improvements in patient-reported symptoms, potentially positioning the drug in a disease area with no approved treatments. Reuters article
  • Neutral Sentiment: The positive data may improve dazodalibep’s commercial prospects, but it remains investigational; further development and regulatory review are needed before it can generate sales. Amgen announcement
  • Negative Sentiment: Despite the encouraging results, some coverage reported that Amgen shares slipped, indicating investors may be taking a cautious or “sell-the-news” approach rather than immediately pricing in the drug’s longer-term potential. MSN article

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AMGN shares. Mizuho lifted their price objective on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Morgan Stanley increased their target price on shares of Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Canaccord Genuity Group raised their target price on shares of Amgen from $384.00 to $440.00 and gave the company a “hold” rating in a research report on Wednesday, November 4th. Piper Sandler raised their target price on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Finally, The Goldman Sachs Group lifted their price target on shares of Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $422.76.

Check Out Our Latest Research Report on AMGN

Amgen Company Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.